CVAC CureVac | $2.33
+0.9% | 4/25/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $12.00 -> $4.00 | Low | View details for SVB Leerink rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
TNDM Tandem Diabetes Care | $35.24
-0.9% | 4/25/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $34.00 -> $45.00 | Low | View details for SVB Leerink rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
RNAC Cartesian Therapeutics | $21.03
+0.6% | 4/23/2024 | Initiated by | SVB Leerink | - | Outperform | $39.00 | Low | View details for SVB Leerink rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $21.00
+11.3% | 4/16/2024 | Initiated by | SVB Leerink | - | Outperform | $47.00 | Low | View details for SVB Leerink rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $8.52
| 4/15/2024 | Initiated by | SVB Leerink | - | Outperform | $20.00 | Low | View details for SVB Leerink rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $15.72
+1.7% | 4/15/2024 | Initiated by | SVB Leerink | - | Outperform | $32.00 | Low | View details for SVB Leerink rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
|
ALPN Alpine Immune Sciences | $64.56
-0.1% | 4/12/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $42.00 -> $65.00 | Low | View details for SVB Leerink rating of Alpine Immune Sciences (NASDAQ:ALPN) on 4/12/2024 |
SWAV Shockwave Medical | $330.00
+0.3% | 4/8/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $361.00 -> $335.00 | Low | View details for SVB Leerink rating of Shockwave Medical (NASDAQ:SWAV) on 4/8/2024 |
ARDX Ardelyx | $6.42
+1.7% | 4/5/2024 | Initiated by | SVB Leerink | - | Outperform | $14.00 | Low | View details for SVB Leerink rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $6.44
+1.7% | 4/3/2024 | Initiated by | SVB Leerink | - | Outperform | $25.00 | Low | View details for SVB Leerink rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $66.86
+1.2% | 4/1/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $69.00 -> $110.00 | Low | View details for SVB Leerink rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $4.06
+3.6% | 3/25/2024 | Initiated by | SVB Leerink | - | Outperform | $26.00 | Low | View details for SVB Leerink rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
FUSN Fusion Pharmaceuticals | $21.42
+0.1% | 3/19/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $17.00 -> $21.00 | N/A | View details for SVB Leerink rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 3/19/2024 |
WBA Walgreens Boots Alliance | $17.70
+0.6% | 3/18/2024 | Target Lowered by | SVB Leerink | - | Market Perform -> Market Perform | $23.00 -> $22.00 | Low | View details for SVB Leerink rating of Walgreens Boots Alliance (NASDAQ:WBA) on 3/18/2024 |
MIRM Mirum Pharmaceuticals | $24.46
-0.1% | 3/18/2024 | Target Lowered by | SVB Leerink | - | Outperform -> Outperform | $44.00 -> $43.00 | Low | View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 3/18/2024 |
RGLS Regulus Therapeutics | $2.42
+6.6% | 3/18/2024 | Initiated by | SVB Leerink | - | Outperform | $6.00 | Low | View details for SVB Leerink rating of Regulus Therapeutics (NASDAQ:RGLS) on 3/18/2024 |
SPRB Spruce Biosciences | $0.70
-0.1% | 3/14/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $9.00 -> $2.00 | Low | View details for SVB Leerink rating of Spruce Biosciences (NASDAQ:SPRB) on 3/14/2024 |
AMLX Amylyx Pharmaceuticals | $1.76
-1.1% | 3/11/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $16.19
+0.8% | 3/6/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $37.00 | Low | View details for SVB Leerink rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $8.35
+3.2% | 3/5/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $6.00 -> $18.00 | Low | View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $15.47
-2.9% | 3/4/2024 | Initiated by | SVB Leerink | - | Outperform | $48.00 | Low | View details for SVB Leerink rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
WBA Walgreens Boots Alliance | $17.70
+0.6% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $23.00 | Low | View details for SVB Leerink rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $30.57
+0.7% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $42.00 | Low | View details for SVB Leerink rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
RCM R1 RCM | $11.90
+0.7% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $14.00 | Low | View details for SVB Leerink rating of R1 RCM (NASDAQ:RCM) on 2/26/2024 |
PGNY Progyny | $32.04
-1.4% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $49.00 | Low | View details for SVB Leerink rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
PINC Premier | $20.96
+0.7% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $22.50 | Low | View details for SVB Leerink rating of Premier (NASDAQ:PINC) on 2/26/2024 |
PDCO Patterson Companies | $25.77
-0.1% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $36.00 | Low | View details for SVB Leerink rating of Patterson Companies (NASDAQ:PDCO) on 2/26/2024 |
OMI Owens & Minor | $25.09
+4.0% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $24.00 | Low | View details for SVB Leerink rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $543.30
+0.6% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $600.00 | Low | View details for SVB Leerink rating of McKesson (NYSE:MCK) on 2/26/2024 |
LH Laboratory Co. of America | $198.40
+0.0% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $260.00 | Low | View details for SVB Leerink rating of Laboratory Co. of America (NYSE:LH) on 2/26/2024 |
IQV IQVIA | $234.88
+0.4% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $290.00 | Low | View details for SVB Leerink rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HIMS Hims & Hers Health | $12.50
+1.9% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $10.00 | Low | View details for SVB Leerink rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $7.19
+1.6% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $8.00 | Low | View details for SVB Leerink rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
NVST Envista | $20.39
+1.8% | 2/26/2024 | Initiated by | SVB Leerink | - | Underperform | $19.00 | Low | View details for SVB Leerink rating of Envista (NYSE:NVST) on 2/26/2024 |
TDOC Teladoc Health | $13.01
-2.4% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $17.00 | Low | View details for SVB Leerink rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
CVS CVS Health | $67.18
-0.2% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $88.00 | Low | View details for SVB Leerink rating of CVS Health (NYSE:CVS) on 2/26/2024 |
HSIC Henry Schein | $73.13
+0.4% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $78.00 | Low | View details for SVB Leerink rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
DGX Quest Diagnostics | $134.26
-0.9% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $135.00 | Low | View details for SVB Leerink rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
DOCS Doximity | $23.82
+1.0% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $32.00 | Low | View details for SVB Leerink rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $16.57
+1.7% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $19.00 | Low | View details for SVB Leerink rating of Certara (NASDAQ:CERT) on 2/26/2024 |
Protect Yourself While There’s Still Time … (Ad) The next step of the Fed's control is here.
Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week.
Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. |
COR Cencora | $240.88
+0.5% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $261.00 | Low | View details for SVB Leerink rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $103.21
-0.6% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $125.00 | Low | View details for SVB Leerink rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
ALGN Align Technology | $309.02
-0.5% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $310.00 | Low | View details for SVB Leerink rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
ACCD Accolade | $7.89
-14.1% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $16.00 | Low | View details for SVB Leerink rating of Accolade (NASDAQ:ACCD) on 2/26/2024 |
APLT Applied Therapeutics | $4.28
+1.2% | 2/22/2024 | Initiated by | SVB Leerink | - | Outperform | $12.00 | Low | View details for SVB Leerink rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT RAPT Therapeutics | $8.10
+3.8% | 2/21/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $42.00 -> $10.00 | Low | View details for SVB Leerink rating of RAPT Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
BTSG BrightSpring Health Services | $10.58
+1.6% | 2/20/2024 | Initiated by | SVB Leerink | - | Outperform | $15.00 | Low | View details for SVB Leerink rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
CBAY CymaBay Therapeutics | $32.48
| 2/20/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $32.50 | Low | View details for SVB Leerink rating of CymaBay Therapeutics (NASDAQ:CBAY) on 2/20/2024 |
ENGN enGene | $15.50
+5.3% | 2/20/2024 | Initiated by | SVB Leerink | - | Outperform | $31.00 | Low | View details for SVB Leerink rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
SYBX Synlogic | $1.86
| 2/9/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $269.98
+0.2% | 2/7/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $324.00 -> $318.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $233.85
-0.9% | 2/5/2024 | Initiated by | SVB Leerink | - | Outperform | $330.00 | Low | View details for SVB Leerink rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
TSVT 2seventy bio | $4.26
-0.7% | 1/31/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $5.00 -> $18.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 |
NPCE NeuroPace | $13.39
+3.1% | 1/30/2024 | Initiated by | SVB Leerink | - | Outperform | $22.00 | Low | View details for SVB Leerink rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $13.73
-3.7% | 1/29/2024 | Initiated by | SVB Leerink | - | Outperform | $30.00 | Low | View details for SVB Leerink rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $4.30
| 1/23/2024 | Initiated by | SVB Leerink | - | Outperform | $12.00 | Low | View details for SVB Leerink rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AXNX Axonics | $66.69
+0.2% | 1/12/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $71.00 | Low | View details for SVB Leerink rating of Axonics (NASDAQ:AXNX) on 1/12/2024 |
AGL agilon health | $5.00
-2.5% | 1/8/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of agilon health (NYSE:AGL) on 1/8/2024 |
ALVR AlloVir | $0.80
-0.4% | 12/22/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $4.66
-1.7% | 12/19/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $5.00 -> $12.00 | Low | View details for SVB Leerink rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
RPHM Reneo Pharmaceuticals | $1.67
+1.2% | 12/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Reneo Pharmaceuticals (NASDAQ:RPHM) on 12/15/2023 |
INCY Incyte | $51.68
+1.0% | 12/13/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $78.00 | Low | View details for SVB Leerink rating of Incyte (NASDAQ:INCY) on 12/13/2023 |
NBTX Nanobiotix | $5.74
-2.9% | 12/8/2023 | Initiated by | SVB Leerink | - | Outperform | $11.00 | Low | View details for SVB Leerink rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TNYA Tenaya Therapeutics | $4.31
+2.1% | 11/30/2023 | Initiated by | SVB Leerink | - | Outperform | $7.00 | Low | View details for SVB Leerink rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
LXEO Lexeo Therapeutics | $12.50
+2.8% | 11/28/2023 | Initiated by | SVB Leerink | - | Outperform | $19.00 | Low | View details for SVB Leerink rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $15.78
+0.3% | 11/14/2023 | Initiated by | SVB Leerink | - | Outperform | $20.00 | Low | View details for SVB Leerink rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
ZNTL Zentalis Pharmaceuticals | $11.06
+0.7% | 11/7/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $15.00 | Low | View details for SVB Leerink rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $4.26
-0.7% | 10/30/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $6.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
BEAM Beam Therapeutics | $21.38
-1.0% | 10/20/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $75.00 -> $20.00 | Low | View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
FDMT 4D Molecular Therapeutics | $23.25
-1.2% | 10/18/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $24.00 | Low | View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
AXGN AxoGen | $6.63
+1.7% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $9.00 | Low | View details for SVB Leerink rating of AxoGen (NASDAQ:AXGN) on 10/16/2023 |
AXNX Axonics | $66.69
+0.2% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $70.00 | Low | View details for SVB Leerink rating of Axonics (NASDAQ:AXNX) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $51.83
-0.9% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $37.00 | Low | View details for SVB Leerink rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
DXCM DexCom | $124.34
-9.9% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $110.00 | Low | View details for SVB Leerink rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
EW Edwards Lifesciences | $86.43
-1.8% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $75.00 | Low | View details for SVB Leerink rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
SWAV Shockwave Medical | $330.00
+0.3% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $263.00 | Low | View details for SVB Leerink rating of Shockwave Medical (NASDAQ:SWAV) on 10/16/2023 |
INSP Inspire Medical Systems | $237.45
+2.8% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $159.00 | Low | View details for SVB Leerink rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
TNDM Tandem Diabetes Care | $35.24
-0.9% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $21.00 | Low | View details for SVB Leerink rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
ISRG Intuitive Surgical | $375.33
+0.6% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $342.00 | Low | View details for SVB Leerink rating of Intuitive Surgical (NASDAQ:ISRG) on 10/16/2023 |
VCEL Vericel | $46.05
+1.3% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $42.00 | Low | View details for SVB Leerink rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
PODD Insulet | $166.19
+1.2% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $184.00 | Low | View details for SVB Leerink rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
AMGN Amgen | $269.98
+0.2% | 10/11/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $267.00 -> $318.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
NBIX Neurocrine Biosciences | $135.99
-1.3% | 10/6/2023 | Target Raised by | SVB Leerink | Analyst M. Goodman | | $125.00 -> $135.00 | Low | View details for SVB Leerink rating of Neurocrine Biosciences (NASDAQ:NBIX) on 10/6/2023 |
GPCR Structure Therapeutics | $38.94
-0.1% | 9/29/2023 | Target Raised by | SVB Leerink | - | | $46.00 -> $97.00 | Low | View details for SVB Leerink rating of Structure Therapeutics (NASDAQ:GPCR) on 9/29/2023 |
SPRY ARS Pharmaceuticals | $8.35
+3.2% | 9/21/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
PTCT PTC Therapeutics | $28.57
+12.1% | 9/18/2023 | Target Lowered by | SVB Leerink | Analyst J. Schwartz | | $44.00 -> $30.00 | Low | View details for SVB Leerink rating of PTC Therapeutics (NASDAQ:PTCT) on 9/18/2023 |
SPRB Spruce Biosciences | $0.70
-0.1% | 9/8/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $3.00 -> $9.00 | Low | View details for SVB Leerink rating of Spruce Biosciences (NASDAQ:SPRB) on 9/8/2023 |
GLTO Galecto | $0.70
+5.4% | 8/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $13.00 -> $2.00 | Low | View details for SVB Leerink rating of Galecto (NASDAQ:GLTO) on 8/15/2023 |
DSGN Design Therapeutics | $3.78
+0.5% | 8/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $6.00 | Low | View details for SVB Leerink rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $65.34
+0.8% | 8/15/2023 | Initiated by | SVB Leerink | - | Outperform | $58.00 | Low | View details for SVB Leerink rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
The Next Step of Their Control Is Here … (Ad) Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years.
What does this mean?
It means the government has more time — and more ways — to surveil and control you. 4 simple steps to protect your privacy and money before it’s too late. |
EXEL Exelixis | $23.70
+0.7% | 8/8/2023 | Initiated by | SVB Leerink | - | Market Perform | $18.00 | Low | View details for SVB Leerink rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $39.94
+3.4% | 8/8/2023 | Initiated by | SVB Leerink | - | Outperform | $33.00 | Low | View details for SVB Leerink rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
NUVL Nuvalent | $66.86
+1.2% | 8/8/2023 | Initiated by | SVB Leerink | - | Market Perform | $42.00 | Low | View details for SVB Leerink rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
NVCR NovoCure | $12.64
+3.4% | 8/4/2023 | Initiated by | SVB Leerink | - | Outperform | $51.00 | Low | View details for SVB Leerink rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
BLTE Belite Bio | $39.75
+4.6% | 7/26/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $25.00 | Low | View details for SVB Leerink rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
NBIX Neurocrine Biosciences | $135.99
-1.3% | 7/24/2023 | Upgraded by | SVB Leerink | Analyst M. Goodman | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
CYRX Cryoport | $16.38
+2.2% | 7/13/2023 | Downgraded by | SVB Leerink | Analyst P. Souda | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Cryoport (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol-Myers Squibb | $44.85
+0.3% | 7/10/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Market Perform | | Low | View details for SVB Leerink rating of Bristol-Myers Squibb (NYSE:BMY) on 7/10/2023 |
EHAB Enhabit | $10.03
+1.6% | 6/20/2023 | Reiterated by | SVB Leerink | Analyst W. Mayo | Underperform | | Low | View details for SVB Leerink rating of Enhabit (NYSE:EHAB) on 6/20/2023 |
OCS Oculis | $12.02
+0.6% | 6/12/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | | Low | View details for SVB Leerink rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
BPMC Blueprint Medicines | $93.00
+2.5% | 6/5/2023 | Downgraded by | SVB Leerink | Analyst A. Berens | Market Perform -> Underperform | | Low | View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 6/5/2023 |
ELEV Elevation Oncology | $3.62
-0.8% | 5/30/2023 | Upgraded by | SVB Leerink | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Elevation Oncology (NASDAQ:ELEV) on 5/30/2023 |
BOLT Bolt Biotherapeutics | $1.11
-4.4% | 5/12/2023 | Upgraded by | SVB Leerink | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/12/2023 |
ARWR Arrowhead Pharmaceuticals | $22.12
+1.1% | 5/12/2023 | Downgraded by | SVB Leerink | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
DHR Danaher | $246.58
+0.3% | 5/1/2023 | Reiterated by | SVB Leerink | Analyst P. Souda | Outperform | | Low | View details for SVB Leerink rating of Danaher (NYSE:DHR) on 5/1/2023 |
PRTA Prothena | $20.87
+1.5% | 4/24/2023 | Reiterated by | SVB Leerink | Analyst R. Li | Outperform | | Low | View details for SVB Leerink rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
GNFT Genfit | $3.49
+1.2% | 4/14/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | | Low | View details for SVB Leerink rating of Genfit (NASDAQ:GNFT) on 4/14/2023 |
CNTB Connect Biopharma | $1.33
-2.2% | 4/12/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | | Low | View details for SVB Leerink rating of Connect Biopharma (NASDAQ:CNTB) on 4/12/2023 |
ARWR Arrowhead Pharmaceuticals | $22.12
+1.1% | 4/12/2023 | Upgraded by | SVB Leerink | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $22.80
+2.7% | 4/11/2023 | Reiterated by | SVB Leerink | Analyst R. Ruiz | Market Perform | $25.00 | Low | View details for SVB Leerink rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
ACLX Arcellx | $51.92
+1.1% | 3/30/2023 | Target Raised by | SVB Leerink | - | Outperform | $35.00 -> $39.00 | Low | View details for SVB Leerink rating of Arcellx (NASDAQ:ACLX) on 3/30/2023 |
ABT Abbott Laboratories | $107.53
+0.6% | 3/31/2023 | Target Raised by | SVB Leerink | - | Market Perform | $90.00 -> $102.00 | Low | View details for SVB Leerink rating of Abbott Laboratories (NYSE:ABT) on 3/31/2023 |
REGN Regeneron Pharmaceuticals | $883.20
-0.8% | 3/27/2023 | Upgraded by | SVB Leerink | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
PTCT PTC Therapeutics | $28.57
+12.1% | 3/17/2023 | Reiterated by | SVB Leerink | Analyst J. Schwartz | Market Perform | $48.00 | Low | View details for SVB Leerink rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
CNTA Centessa Pharmaceuticals | $8.92
-0.1% | 3/17/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | $6.00 | Low | View details for SVB Leerink rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023 |
HALO Halozyme Therapeutics | $38.57
+0.3% | 3/16/2023 | Downgraded by | SVB Leerink | Analyst D. Risinger | Outperform -> Market Perform | $42.00 | Low | View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
MORF Morphic | $28.07
+0.3% | 3/8/2023 | Target Raised by | SVB Leerink | - | Outperform | $45.00 -> $56.00 | Low | View details for SVB Leerink rating of Morphic (NASDAQ:MORF) on 3/8/2023 |
ARGX argenx | $372.80
+1.1% | 3/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $430.00 -> $435.00 | Low | View details for SVB Leerink rating of argenx (NASDAQ:ARGX) on 3/3/2023 |
GPCR Structure Therapeutics | $38.94
-0.1% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | | Low | View details for SVB Leerink rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
CGEN Compugen | $1.92
+1.1% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst D. Graybosch | Outperform | | Low | View details for SVB Leerink rating of Compugen (NASDAQ:CGEN) on 2/28/2023 |
IRON Disc Medicine | $27.55
+3.9% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | $36.00 | Low | View details for SVB Leerink rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
XNCR Xencor | $19.98
+3.9% | 2/23/2023 | Reiterated by | SVB Leerink | Analyst J. Chang | Outperform | | Low | View details for SVB Leerink rating of Xencor (NASDAQ:XNCR) on 2/23/2023 |
MRNA Moderna | $107.97
+1.7% | 2/24/2023 | Downgraded by | SVB Leerink | Analyst M. Foroohar | Market Perform -> Underperform | $111.00 -> $93.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
NKTR Nektar Therapeutics | $1.32
| 2/24/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $5.00 -> $3.00 | N/A | View details for SVB Leerink rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
BPMC Blueprint Medicines | $93.00
+2.5% | 2/24/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $45.00 -> $38.00 | Low | View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $41.59
-0.6% | 2/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $34.00 -> $27.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $13.01
-2.4% | 2/23/2023 | Upgraded by | SVB Leerink | Analyst S. Davis | Market Perform -> Outperform | $34.00 | Low | View details for SVB Leerink rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $159.62
-4.6% | 2/10/2023 | Upgraded by | SVB Leerink | Analyst D. Risinger | Underperform -> Market Perform | $135.00 -> $153.00 | Low | View details for SVB Leerink rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
ENTA Enanta Pharmaceuticals | $12.37
-0.9% | 2/9/2023 | Reiterated by | SVB Leerink | - | Market Perform | $49.00 | Low | View details for SVB Leerink rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 2/9/2023 |
CBAY CymaBay Therapeutics | $32.48
| 2/8/2023 | Target Raised by | SVB Leerink | - | Outperform | $10.00 -> $12.00 | Low | View details for SVB Leerink rating of CymaBay Therapeutics (NASDAQ:CBAY) on 2/8/2023 |
CNTB Connect Biopharma | $1.33
-2.2% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $9.00 -> $7.00 | Low | View details for SVB Leerink rating of Connect Biopharma (NASDAQ:CNTB) on 2/8/2023 |
EQ Equillium | $1.71
-5.5% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $12.00 -> $7.00 | Low | View details for SVB Leerink rating of Equillium (NASDAQ:EQ) on 2/8/2023 |
CI The Cigna Group | $354.47
0.0% | 2/8/2023 | Target Raised by | SVB Leerink | - | Market Perform | $309.00 -> $335.00 | Low | View details for SVB Leerink rating of The Cigna Group (NYSE:CI) on 2/8/2023 |
PINC Premier | $20.96
+0.7% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $46.00 -> $42.00 | Low | View details for SVB Leerink rating of Premier (NASDAQ:PINC) on 2/8/2023 |
ILMN Illumina | $122.28
+1.0% | 2/8/2023 | Target Raised by | SVB Leerink | Analyst P. Souda | Outperform | $249.00 -> $250.00 | Low | View details for SVB Leerink rating of Illumina (NASDAQ:ILMN) on 2/8/2023 |
VRTX Vertex Pharmaceuticals | $397.48
-0.1% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $374.00 -> $365.00 | Low | View details for SVB Leerink rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023 |
INCY Incyte | $51.68
+1.0% | 2/8/2023 | Reiterated by | SVB Leerink | - | Underperform | $63.00 | Low | View details for SVB Leerink rating of Incyte (NASDAQ:INCY) on 2/8/2023 |
DCPH Deciphera Pharmaceuticals | $14.65
+3.3% | 2/7/2023 | Target Raised by | SVB Leerink | - | Outperform | $28.00 -> $30.00 | Low | View details for SVB Leerink rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 2/7/2023 |
GMAB Genmab A/S | $28.15
+2.5% | 2/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $33.00 -> $36.00 | Low | View details for SVB Leerink rating of Genmab A/S (NASDAQ:GMAB) on 2/6/2023 |
FDMT 4D Molecular Therapeutics | $23.25
-1.2% | 2/6/2023 | Target Lowered by | SVB Leerink | Analyst M. Foroohar | Market Perform | $15.00 -> $14.00 | Low | View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 2/6/2023 |
Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad) 4x Better than Bitcoin
Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> |
IMVT Immunovant | $27.17
-2.1% | 2/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $14.00 -> $21.00 | Low | View details for SVB Leerink rating of Immunovant (NASDAQ:IMVT) on 2/6/2023 |
REGN Regeneron Pharmaceuticals | $883.20
-0.8% | 2/6/2023 | Target Raised by | SVB Leerink | Analyst D. Risinger | Market Perform | $770.00 -> $834.00 | Low | View details for SVB Leerink rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/6/2023 |
GILD Gilead Sciences | $65.42
+0.2% | 2/3/2023 | Target Raised by | SVB Leerink | Analyst D. Risinger | Market Perform | $81.00 -> $91.00 | Low | View details for SVB Leerink rating of Gilead Sciences (NASDAQ:GILD) on 2/3/2023 |
TECH Bio-Techne | $64.06
+2.2% | 2/3/2023 | Target Lowered by | SVB Leerink | - | Outperform | $125.00 -> $110.00 | Low | View details for SVB Leerink rating of Bio-Techne (NASDAQ:TECH) on 2/3/2023 |
BMRN BioMarin Pharmaceutical | $80.91
-1.5% | 2/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $122.00 -> $130.00 | Low | View details for SVB Leerink rating of BioMarin Pharmaceutical (NASDAQ:BMRN) on 2/3/2023 |
IONS Ionis Pharmaceuticals | $41.59
-0.6% | 2/3/2023 | Target Raised by | SVB Leerink | - | Market Perform | $33.00 -> $34.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/3/2023 |
MRK Merck & Co., Inc. | $131.20
+0.4% | 2/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $120.00 -> $122.00 | Low | View details for SVB Leerink rating of Merck & Co., Inc. (NYSE:MRK) on 2/3/2023 |
KALV KalVista Pharmaceuticals | $10.78
+2.8% | 2/3/2023 | Target Lowered by | SVB Leerink | - | Outperform | $30.00 -> $20.00 | Low | View details for SVB Leerink rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 2/3/2023 |
TMO Thermo Fisher Scientific | $573.60
+0.3% | 2/2/2023 | Target Raised by | SVB Leerink | - | Outperform | $620.00 -> $630.00 | Low | View details for SVB Leerink rating of Thermo Fisher Scientific (NYSE:TMO) on 2/2/2023 |
HOLX Hologic | $75.98
+0.4% | 2/2/2023 | Target Raised by | SVB Leerink | - | Outperform | $90.00 -> $93.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 2/2/2023 |
AMGN Amgen | $269.98
+0.2% | 2/2/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $282.00 -> $267.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 2/2/2023 |
PFE Pfizer | $25.38
+0.5% | 2/1/2023 | Target Lowered by | SVB Leerink | Analyst David Risinger | Market Perform | $49.00 -> $48.00 | Low | View details for SVB Leerink rating of Pfizer (NYSE:PFE) on 2/1/2023 |
OPRX OptimizeRx | $10.12
+15.0% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform | | Low | View details for SVB Leerink rating of OptimizeRx (NASDAQ:OPRX) on 1/27/2023 |
OMCL Omnicell | $27.86
+2.7% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Market Perform | | Low | View details for SVB Leerink rating of Omnicell (NASDAQ:OMCL) on 1/27/2023 |
IQV IQVIA | $234.88
+0.4% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform | | Low | View details for SVB Leerink rating of IQVIA (NYSE:IQV) on 1/27/2023 |
DNLI Denali Therapeutics | $15.43
+3.1% | 1/30/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $50.00 | Low | View details for SVB Leerink rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023 |
AVIR Atea Pharmaceuticals | $3.71
+0.5% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $8.00 -> $6.00 | Low | View details for SVB Leerink rating of Atea Pharmaceuticals (NASDAQ:AVIR) on 1/27/2023 |
ENTA Enanta Pharmaceuticals | $12.37
-0.9% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $50.00 -> $49.00 | Low | View details for SVB Leerink rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 1/27/2023 |
SCPH scPharmaceuticals | $4.49
+3.2% | 1/27/2023 | Target Raised by | SVB Leerink | Analyst R. Ruiz | Outperform | $12.00 -> $13.00 | Low | View details for SVB Leerink rating of scPharmaceuticals (NASDAQ:SCPH) on 1/27/2023 |
VIR Vir Biotechnology | $8.23
+7.9% | 1/27/2023 | Target Lowered by | SVB Leerink | Analyst R. Ruiz | Outperform | $45.00 -> $43.00 | Low | View details for SVB Leerink rating of Vir Biotechnology (NASDAQ:VIR) on 1/27/2023 |
XERS Xeris Biopharma | $1.75
+2.9% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Outperform | $6.00 -> $5.00 | Low | View details for SVB Leerink rating of Xeris Biopharma (NASDAQ:XERS) on 1/27/2023 |
ELV Elevance Health | $537.26
-0.4% | 1/26/2023 | Reiterated by | SVB Leerink | Analyst W. Mayo | Outperform | $580.00 | Low | View details for SVB Leerink rating of Elevance Health (NYSE:ELV) on 1/26/2023 |
PLRX Pliant Therapeutics | $11.81
-0.6% | 1/24/2023 | Target Raised by | SVB Leerink | - | Outperform | $33.00 -> $45.00 | Low | View details for SVB Leerink rating of Pliant Therapeutics (NASDAQ:PLRX) on 1/24/2023 |
BHVN Biohaven | $38.97
+1.1% | 1/24/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $24.00 | Low | View details for SVB Leerink rating of Biohaven (NYSE:BHVN) on 1/24/2023 |
MRK Merck & Co., Inc. | $131.20
+0.4% | 1/23/2023 | Target Raised by | SVB Leerink | - | Outperform | $112.00 -> $120.00 | Low | View details for SVB Leerink rating of Merck & Co., Inc. (NYSE:MRK) on 1/23/2023 |
MRNS Marinus Pharmaceuticals | $1.41
-1.1% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $27.00 -> $23.00 | Low | View details for SVB Leerink rating of Marinus Pharmaceuticals (NASDAQ:MRNS) on 1/23/2023 |
RLMD Relmada Therapeutics | $3.83
+3.5% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $42.00 -> $10.00 | Low | View details for SVB Leerink rating of Relmada Therapeutics (NASDAQ:RLMD) on 1/23/2023 |
ALNY Alnylam Pharmaceuticals | $143.31
-0.3% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $144.00 -> $143.00 | Low | View details for SVB Leerink rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/23/2023 |
ALVR AlloVir | $0.80
-0.4% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $25.00 -> $19.00 | Low | View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 1/23/2023 |
BBIO BridgeBio Pharma | $24.88
+2.3% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $23.00 -> $19.00 | Low | View details for SVB Leerink rating of BridgeBio Pharma (NASDAQ:BBIO) on 1/23/2023 |
BEAM Beam Therapeutics | $21.38
-1.0% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $81.00 -> $77.00 | Low | View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 1/23/2023 |
BLUE bluebird bio | $0.92
+1.1% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $9.00 -> $8.00 | Low | View details for SVB Leerink rating of bluebird bio (NASDAQ:BLUE) on 1/23/2023 |
EDIT Editas Medicine | $5.32
+1.9% | 1/23/2023 | Target Raised by | SVB Leerink | Analyst R. Bienkowski | Market Perform | $6.00 -> $7.00 | Low | View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 1/23/2023 |
IONS Ionis Pharmaceuticals | $41.59
-0.6% | 1/23/2023 | Target Raised by | SVB Leerink | - | Market Perform | $32.00 -> $33.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 1/23/2023 |
NTLA Intellia Therapeutics | $20.76
+3.7% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $86.00 -> $84.00 | Low | View details for SVB Leerink rating of Intellia Therapeutics (NASDAQ:NTLA) on 1/23/2023 |
RCKT Rocket Pharmaceuticals | $21.98
-0.5% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $50.00 -> $49.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 1/23/2023 |
RGNX REGENXBIO | $16.19
+0.8% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $15.00 -> $14.00 | Low | View details for SVB Leerink rating of REGENXBIO (NASDAQ:RGNX) on 1/23/2023 |
RXRX Recursion Pharmaceuticals | $8.12
+3.6% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $9.00 -> $8.00 | Low | View details for SVB Leerink rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 1/23/2023 |
SRPT Sarepta Therapeutics | $128.77
+1.1% | 1/20/2023 | Reiterated by | SVB Leerink | - | Outperform | $160.00 | Low | View details for SVB Leerink rating of Sarepta Therapeutics (NASDAQ:SRPT) on 1/20/2023 |
ZYME Zymeworks | $8.26
+1.8% | 1/20/2023 | Target Raised by | SVB Leerink | Analyst A. Berens | Market Perform | $8.00 -> $10.00 | Low | View details for SVB Leerink rating of Zymeworks (NYSE:ZYME) on 1/20/2023 |
BGNE BeiGene | $153.58
+3.4% | 1/20/2023 | Target Raised by | SVB Leerink | - | Outperform | $236.00 -> $300.00 | Low | View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 1/20/2023 |
JNJ Johnson & Johnson | $146.14
-0.5% | 1/20/2023 | Target Lowered by | SVB Leerink | - | Outperform | $194.00 -> $186.00 | Low | View details for SVB Leerink rating of Johnson & Johnson (NYSE:JNJ) on 1/20/2023 |
MRNA Moderna | $107.97
+1.7% | 1/18/2023 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $102.00 -> $111.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 1/18/2023 |
EOLS Evolus | $11.43
-0.3% | 1/19/2023 | Target Raised by | SVB Leerink | - | Outperform | $18.00 -> $20.00 | Low | View details for SVB Leerink rating of Evolus (NASDAQ:EOLS) on 1/19/2023 |
VRTX Vertex Pharmaceuticals | $397.48
-0.1% | 1/17/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $374.00 | Low | View details for SVB Leerink rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/17/2023 |
EXAS Exact Sciences | $58.85
+0.1% | 1/12/2023 | Target Raised by | SVB Leerink | - | Outperform | $70.00 -> $75.00 | Low | View details for SVB Leerink rating of Exact Sciences (NASDAQ:EXAS) on 1/12/2023 |
HOLX Hologic | $75.98
+0.4% | 1/12/2023 | Target Raised by | SVB Leerink | - | Outperform | $85.00 -> $90.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 1/12/2023 |
HALO Halozyme Therapeutics | $38.57
+0.3% | 1/11/2023 | Target Lowered by | SVB Leerink | - | Outperform | $62.00 -> $61.00 | Low | View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 1/11/2023 |
MIRM Mirum Pharmaceuticals | $24.46
-0.1% | 1/10/2023 | Target Lowered by | SVB Leerink | - | Outperform | $50.00 -> $39.00 | Low | View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 1/10/2023 |
EDIT Editas Medicine | $5.32
+1.9% | 1/10/2023 | Target Lowered by | SVB Leerink | Analyst R. Bienkowski | Market Perform | $7.00 -> $6.00 | Low | View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 1/10/2023 |
The Next Step of Their Control Is Here … (Ad) Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years.
What does this mean?
It means the government has more time — and more ways — to surveil and control you. 4 simple steps to protect your privacy and money before it’s too late. |
KPTI Karyopharm Therapeutics | $1.06
| 1/10/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $6.00 -> $5.00 | Low | View details for SVB Leerink rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 1/10/2023 |
TSVT 2seventy bio | $4.26
-0.7% | 1/10/2023 | Target Lowered by | SVB Leerink | - | Outperform | $41.00 -> $34.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 1/10/2023 |
VRDN Viridian Therapeutics | $12.88
+1.4% | 1/9/2023 | Target Raised by | SVB Leerink | - | Outperform | $40.00 -> $45.00 | Low | View details for SVB Leerink rating of Viridian Therapeutics (NASDAQ:VRDN) on 1/9/2023 |
BLUE bluebird bio | $0.92
+1.1% | 1/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $8.00 -> $9.00 | Low | View details for SVB Leerink rating of bluebird bio (NASDAQ:BLUE) on 1/6/2023 |
EXAS Exact Sciences | $58.85
+0.1% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $60.00 -> $70.00 | Low | View details for SVB Leerink rating of Exact Sciences (NASDAQ:EXAS) on 1/6/2023 |
HOLX Hologic | $75.98
+0.4% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $78.00 -> $85.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 1/6/2023 |
A Agilent Technologies | $137.74
+1.0% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $160.00 -> $170.00 | Low | View details for SVB Leerink rating of Agilent Technologies (NYSE:A) on 1/6/2023 |
ABCL AbCellera Biologics | $3.76
+3.6% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $18.00 | Low | View details for SVB Leerink rating of AbCellera Biologics (NASDAQ:ABCL) on 1/6/2023 |
MASS 908 Devices | $5.67
+2.0% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $25.00 -> $20.00 | Low | View details for SVB Leerink rating of 908 Devices (NASDAQ:MASS) on 1/6/2023 |
RGEN Repligen | $166.58
+0.6% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $230.00 -> $200.00 | Low | View details for SVB Leerink rating of Repligen (NASDAQ:RGEN) on 1/6/2023 |
TMO Thermo Fisher Scientific | $573.60
+0.3% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $555.00 -> $620.00 | Low | View details for SVB Leerink rating of Thermo Fisher Scientific (NYSE:TMO) on 1/6/2023 |
WAT Waters | $311.30
+1.0% | 1/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $320.00 -> $352.00 | Low | View details for SVB Leerink rating of Waters (NYSE:WAT) on 1/6/2023 |
FATE Fate Therapeutics | $3.80
-1.8% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $62.00 -> $10.00 | N/A | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 1/6/2023 |
IPSC Century Therapeutics | $2.88
-8.6% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $14.00 | Low | View details for SVB Leerink rating of Century Therapeutics (NASDAQ:IPSC) on 1/6/2023 |
AMED Amedisys | $91.79
+0.7% | 1/5/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $96.00 -> $85.00 | Low | View details for SVB Leerink rating of Amedisys (NASDAQ:AMED) on 1/5/2023 |
COGT Cogent Biosciences | $6.02
+0.2% | 1/5/2023 | Target Raised by | SVB Leerink | - | Outperform | $18.00 -> $20.00 | Low | View details for SVB Leerink rating of Cogent Biosciences (NASDAQ:COGT) on 1/5/2023 |
PGNY Progyny | $32.04
-1.4% | 1/5/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform -> Market Perform | $59.00 -> $34.00 | Low | View details for SVB Leerink rating of Progyny (NASDAQ:PGNY) on 1/5/2023 |
PHR Phreesia | $20.61
+0.7% | 1/5/2023 | Target Raised by | SVB Leerink | Analyst S. Davis | Outperform | $34.00 -> $39.00 | Low | View details for SVB Leerink rating of Phreesia (NYSE:PHR) on 1/5/2023 |
DCPH Deciphera Pharmaceuticals | $14.65
+3.3% | 1/4/2023 | Target Raised by | SVB Leerink | - | Outperform | $25.00 -> $28.00 | Low | View details for SVB Leerink rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 1/4/2023 |
AMGN Amgen | $269.98
+0.2% | 12/22/2022 | Target Raised by | SVB Leerink | - | Market Perform | $256.00 -> $282.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 12/22/2022 |
RCKT Rocket Pharmaceuticals | $21.98
-0.5% | 12/22/2022 | Target Lowered by | SVB Leerink | - | Outperform | $54.00 -> $50.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/22/2022 |
MDGL Madrigal Pharmaceuticals | $193.33
-0.5% | 12/20/2022 | Target Raised by | SVB Leerink | - | Outperform | $145.00 -> $315.00 | Low | View details for SVB Leerink rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 12/20/2022 |
NAMS NewAmsterdam Pharma | $21.99
+2.6% | 12/20/2022 | Initiated by | SVB Leerink | Analyst R. Ruiz | Outperform | $19.00 | Low | View details for SVB Leerink rating of NewAmsterdam Pharma (NASDAQ:NAMS) on 12/20/2022 |
PCVX Vaxcyte | $60.72
+1.1% | 12/16/2022 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | $60.00 | Low | View details for SVB Leerink rating of Vaxcyte (NASDAQ:PCVX) on 12/16/2022 |
HCA HCA Healthcare | $306.69
-2.4% | 12/16/2022 | Target Raised by | SVB Leerink | - | Outperform | $238.00 -> $286.00 | Low | View details for SVB Leerink rating of HCA Healthcare (NYSE:HCA) on 12/16/2022 |
LLY Eli Lilly and Company | $733.51
+1.2% | 12/16/2022 | Target Raised by | SVB Leerink | - | Outperform | $384.00 -> $410.00 | Low | View details for SVB Leerink rating of Eli Lilly and Company (NYSE:LLY) on 12/16/2022 |
ROIV Roivant Sciences | $11.03
+1.4% | 12/19/2022 | Target Raised by | SVB Leerink | - | Outperform | $8.00 -> $10.00 | Low | View details for SVB Leerink rating of Roivant Sciences (NASDAQ:ROIV) on 12/19/2022 |
KYMR Kymera Therapeutics | $33.37
+0.1% | 12/15/2022 | Target Raised by | SVB Leerink | Analyst M. Kratky | Market Perform | $26.00 -> $31.00 | Low | View details for SVB Leerink rating of Kymera Therapeutics (NASDAQ:KYMR) on 12/15/2022 |
WVE Wave Life Sciences | $4.66
-1.7% | 12/14/2022 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $2.00 -> $7.00 | Low | View details for SVB Leerink rating of Wave Life Sciences (NASDAQ:WVE) on 12/14/2022 |
MIRM Mirum Pharmaceuticals | $24.46
-0.1% | 12/14/2022 | Target Raised by | SVB Leerink | - | Outperform | $49.00 -> $50.00 | Low | View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 12/14/2022 |
MRNA Moderna | $107.97
+1.7% | 12/13/2022 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $101.00 -> $102.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 12/13/2022 |
NRIX Nurix Therapeutics | $12.36
| 12/13/2022 | Target Lowered by | SVB Leerink | - | Outperform | $37.00 -> $28.00 | Low | View details for SVB Leerink rating of Nurix Therapeutics (NASDAQ:NRIX) on 12/13/2022 |
SPRY ARS Pharmaceuticals | $8.35
+3.2% | 12/13/2022 | Initiated by | SVB Leerink | Analyst Roanna Ruiz | Outperform | $14.00 | Low | View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 12/13/2022 |
FATE Fate Therapeutics | $3.80
-1.8% | 12/13/2022 | Target Lowered by | SVB Leerink | - | Outperform | $64.00 -> $62.00 | Low | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 12/13/2022 |
BGNE BeiGene | $153.58
+3.4% | 12/12/2022 | Target Raised by | SVB Leerink | - | Outperform | $210.00 -> $236.00 | Low | View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 12/12/2022 |
AFMD Affimed | $5.03
+3.1% | 12/12/2022 | Target Lowered by | SVB Leerink | - | Outperform | $100.00 -> $60.00 | Low | View details for SVB Leerink rating of Affimed (NASDAQ:AFMD) on 12/12/2022 |
DSGN Design Therapeutics | $3.78
+0.5% | 12/9/2022 | Target Lowered by | SVB Leerink | - | Outperform | $30.00 -> $22.00 | Low | View details for SVB Leerink rating of Design Therapeutics (NASDAQ:DSGN) on 12/9/2022 |
PHR Phreesia | $20.61
+0.7% | 12/9/2022 | Upgraded by | SVB Leerink | Analyst Stephanie Davis | Market Perform -> Outperform | $31.00 -> $34.00 | Low | View details for SVB Leerink rating of Phreesia (NYSE:PHR) on 12/9/2022 |
REPL Replimune Group | $6.42
+4.4% | 12/7/2022 | Target Raised by | SVB Leerink | - | Outperform | $30.00 -> $34.00 | Low | View details for SVB Leerink rating of Replimune Group (NASDAQ:REPL) on 12/7/2022 |
GOSS Gossamer Bio | $0.67
-0.3% | 12/7/2022 | Target Lowered by | SVB Leerink | - | Outperform | $15.00 -> $10.00 | Low | View details for SVB Leerink rating of Gossamer Bio (NASDAQ:GOSS) on 12/7/2022 |
RCKT Rocket Pharmaceuticals | $21.98
-0.5% | 12/6/2022 | Target Lowered by | SVB Leerink | - | Outperform | $56.00 -> $54.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/6/2022 |
VEEV Veeva Systems | $200.91
+0.9% | 12/2/2022 | Target Lowered by | SVB Leerink | - | Outperform | $242.00 -> $233.00 | Low | View details for SVB Leerink rating of Veeva Systems (NYSE:VEEV) on 12/2/2022 |
NTLA Intellia Therapeutics | $20.76
+3.7% | 12/2/2022 | Target Lowered by | SVB Leerink | - | Outperform | $90.00 -> $86.00 | Low | View details for SVB Leerink rating of Intellia Therapeutics (NASDAQ:NTLA) on 12/2/2022 |
LNTH Lantheus | $65.56
+0.6% | 11/30/2022 | Initiated by | SVB Leerink | - | Outperform | | Low | View details for SVB Leerink rating of Lantheus (NASDAQ:LNTH) on 11/30/2022 |
FUSN Fusion Pharmaceuticals | $21.42
+0.1% | 11/30/2022 | Initiated by | SVB Leerink | Analyst Faisal Khurshid | Outperform | $6.00 | Low | View details for SVB Leerink rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 11/30/2022 |
OABI OmniAb | $4.48
+1.1% | 11/29/2022 | Initiated by | SVB Leerink | Analyst Puneet Souda | Outperform | $6.00 | Low | View details for SVB Leerink rating of OmniAb (NASDAQ:OABI) on 11/29/2022 |
AXSM Axsome Therapeutics | $71.71
+0.3% | 11/29/2022 | Target Raised by | SVB Leerink | - | Outperform | $65.00 -> $85.00 | Low | View details for SVB Leerink rating of Axsome Therapeutics (NASDAQ:AXSM) on 11/29/2022 |
ARWR Arrowhead Pharmaceuticals | $22.12
+1.1% | 11/29/2022 | Target Lowered by | SVB Leerink | - | Market Perform | $33.00 -> $31.00 | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 11/29/2022 |
FATE Fate Therapeutics | $3.80
-1.8% | 11/24/2022 | Target Set by | SVB Leerink | - | | $64.00 | Low | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 11/24/2022 |
ACLX Arcellx | $51.92
+1.1% | 11/24/2022 | Target Lowered by | SVB Leerink | - | | $35.00 | Low | View details for SVB Leerink rating of Arcellx (NASDAQ:ACLX) on 11/24/2022 |
TRVI Trevi Therapeutics | $2.78
+9.4% | 11/22/2022 | Initiated by | SVB Leerink | Analyst T. Smith | Outperform | $6.00 | Low | View details for SVB Leerink rating of Trevi Therapeutics (NASDAQ:TRVI) on 11/22/2022 |
ARVN Arvinas | $32.37
+2.4% | 11/22/2022 | Target Lowered by | SVB Leerink | - | Outperform | $89.00 -> $74.00 | Low | View details for SVB Leerink rating of Arvinas (NASDAQ:ARVN) on 11/22/2022 |
SGRY Surgery Partners | $24.55
-1.2% | 11/22/2022 | Target Lowered by | SVB Leerink | Analyst W. Mayo | Outperform | $55.00 -> $40.00 | Low | View details for SVB Leerink rating of Surgery Partners (NASDAQ:SGRY) on 11/22/2022 |
A Agilent Technologies | $137.74
+1.0% | 11/22/2022 | Target Raised by | SVB Leerink | - | Outperform | $145.00 -> $160.00 | Low | View details for SVB Leerink rating of Agilent Technologies (NYSE:A) on 11/22/2022 |
ALPN Alpine Immune Sciences | $64.56
-0.1% | 11/21/2022 | Initiated by | SVB Leerink | Analyst T. Smith | Outperform | $15.00 | Low | View details for SVB Leerink rating of Alpine Immune Sciences (NASDAQ:ALPN) on 11/21/2022 |
TWST Twist Bioscience | $31.54
+1.5% | 11/21/2022 | Target Lowered by | SVB Leerink | - | Market Perform | $45.00 -> $30.00 | Low | View details for SVB Leerink rating of Twist Bioscience (NASDAQ:TWST) on 11/21/2022 |
EDIT Editas Medicine | $5.32
+1.9% | 11/17/2022 | Target Lowered by | SVB Leerink | Analyst R. Bienkowski | Market Perform | $14.00 -> $7.00 | Low | View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 11/17/2022 |
TBPH Theravance Biopharma | $9.12
-0.2% | 11/17/2022 | Target Raised by | SVB Leerink | - | Outperform | $12.00 -> $14.00 | Low | View details for SVB Leerink rating of Theravance Biopharma (NASDAQ:TBPH) on 11/17/2022 |
COGT Cogent Biosciences | $6.02
+0.2% | 11/17/2022 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $18.00 | Low | View details for SVB Leerink rating of Cogent Biosciences (NASDAQ:COGT) on 11/17/2022 |
OLK Olink Holding AB (publ) | $22.84
-1.0% | 11/15/2022 | Target Raised by | SVB Leerink | - | Outperform | $25.00 -> $27.00 | Low | View details for SVB Leerink rating of Olink Holding AB (publ) (NASDAQ:OLK) on 11/15/2022 |
